These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31265074)

  • 1. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
    Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.
    Wu L; Tsang V; Menzies AM; Sasson SC; Carlino MS; Brown DA; Clifton-Bligh R; Gunton JE
    Diabetes Care; 2023 Jun; 46(6):1292-1299. PubMed ID: 37220262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
    Wu L; Carlino MS; Brown DA; Long GV; Clifton-Bligh R; Mellor R; Moore K; Sasson SC; Menzies AM; Tsang V; Gunton JE
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1301-1307. PubMed ID: 37997380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
    BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
    Wu L; Tsang VHM; Sasson SC; Menzies AM; Carlino MS; Brown DA; Clifton-Bligh R; Gunton JE
    Front Endocrinol (Lausanne); 2021; 12():764138. PubMed ID: 34803927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 18. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
    Gauci ML; Boudou P; Baroudjian B; Vidal-Trecan T; Da Meda L; Madelaine-Chambrin I; Basset-Seguin N; Bagot M; Pages C; Mourah S; Resche-Rigon M; Pinel S; Sassier M; Rouby F; Eftekhari P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.